Completion of Facility Enables Initiation of Phase 3 Clinical Trial of Nepafenac in Patients Undergoing Cataract Surgery AUSTIN, Texas, Sept. 12, 2023 /PRNewswire/ — Mati Therapeutics Inc. (“Mati”) announced that it has completed and now occupies a facility dedicated to manufacturing all…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.